Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Fulvestrant

Maheen Farooq  1 , Shivani P. Patel  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Fulvestrant

Maheen Farooq et al.
Free Books & Documents

Excerpt

Fulvestrant is used in the management and treatment of advanced breast cancer. It is a selective estrogen receptor degrader. This activity outlines the indications, action, and contraindications for fulvestrant as a valuable agent in the treatment of advanced breast carcinoma.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Maheen Farooq declares no relevant financial relationships with ineligible companies.

Disclosure: Shivani Patel declares no relevant financial relationships with ineligible companies.

References

    1. Boér K. Fulvestrant in advanced breast cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2017 Jul;9(7):465-479. - PMC - PubMed
    1. Lee CI, Goodwin A, Wilcken N. Fulvestrant for hormone-sensitive metastatic breast cancer. Cochrane Database Syst Rev. 2017 Jan 03;1(1):CD011093. - PMC - PubMed
    1. Markham A. Alpelisib: First Global Approval. Drugs. 2019 Jul;79(11):1249-1253. - PubMed
    1. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Taran T, Jerusalem G. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020 Feb 06;382(6):514-524. - PubMed
    1. Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M, PALOMA3 Study Group Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16;373(3):209-19. - PubMed

Publication types

LinkOut - more resources